Holen Sie sich die Stockscreener-App
3.79
1.34%
-0.02
Schlusskurs vom Vortag:
$3.81
Offen:
$3.86
24-Stunden-Volumen:
486.01K
Relative Volume:
0.11
Marktkapitalisierung:
$825.09M
Einnahmen:
$35.54M
Nettoeinkommen (Verlust:
$-59.14M
KGV:
-10.42
EPS:
-0.3637
Netto-Cashflow:
$-80.19M
1W Leistung:
+0.24%
1M Leistung:
+25.30%
6M Leistung:
-12.58%
1J Leistung:
+58.61%
1-Tages-Spanne:
$3.685
$3.86
1-Wochen-Bereich:
$3.575
$3.90
52-Wochen-Spanne:
$1.72
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
3.79 | 831.63M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
519.60 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
669.30 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.45 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.66 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.15 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2026-01-20 | Eingeleitet | Guggenheim | Buy |
| 2025-09-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2000 Value Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS:CTMX) added to Russell Microcap Value Benchmark Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell Microcap Index - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 3000E Growth Benchmark - marketscreener.com
CytomX Therapeutics, Inc.(NasdaqGS: CTMX) added to Russell 2500 Value Benchmark - marketscreener.com
Price to book forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to EBIT forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Price to sales forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
Enterprise value to revenue forward of CytomX Therapeutics, Inc. – NASDAQ:CTMX - TradingView
CytomX Therapeutics, Inc. Actuals & Estimates (NASDAQ:CTMX) - TradingView
CTMX Forecast — Price Target — Prediction for 2027 - TradingView
CytomX Shareholders Approve Expanded Equity and Capital Plans - The Globe and Mail
CytomX Therapeutics Amends Equity Incentive and Employee Stock Purchase Plans Following 2026 Shareholder Approval – Minichart - Minichart
CytomX Therapeutics stockholders approve share increases and board elections - Investing.com
CytomX Therapeutics stockholders approve share increases and board elections By Investing.com - Investing.com Canada
Form 8K CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Form 4 CytomX Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
CytomX (CTMX) director Su Zhen awarded 59,000 stock options at $2.96 - Stock Titan
[8-K] CytomX Therapeutics, Inc. Reports Material Event - Stock Titan
Director at CytomX (NASDAQ: CTMX) awarded 59,000 stock options - Stock Titan
Director at CytomX (NASDAQ: CTMX) receives 59,000-stock option award - Stock Titan
CytomX (CTMX) director receives 59,000 stock options at $2.96 - Stock Titan
CytomX (CTMX) director Halley Gilbert receives 59,000 stock options at $2.96 strike - Stock Titan
CytomX (CTMX) director Alan Ashworth receives grant of 59,000 stock options - Stock Titan
CytomX (CTMX) director Elaine Jones awarded 59,000 stock options at $2.96 strike - Stock Titan
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? - Insider Monkey
CytomX Therapeutics Inc (CTMX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CytomX CFO Ogden sells $4,953 in company stock By Investing.com - Investing.com South Africa
CytomX CFO Ogden sells $4,953 in company stock - Investing.com
CytomX Therapeutics (CTMX) CFO sells shares to cover RSU tax withholding - Stock Titan
10 Best Growth Stocks Under $30 to Buy Now - Insider Monkey
CytomX Therapeutics Inc (CTMX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX Therapeutics Inc (CTMX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CytomX Therapeutics Inc (CTMX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CytomX Therapeutics Inc (CTMX) Valuation: PE, PB & Fair Value Analysis - TradingKey
CytomX Therapeutics Inc (CTMX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CytomX Therapeutics Inc (CTMX) Institutional Confidence - TradingKey
CytomX Therapeutics Inc (CTMX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments - Yahoo Finance
Transcript : CytomX Therapeutics, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 09 - marketscreener.com
CytomX Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
CytomX Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as Pipeline AdvancesAdjusted Earnings Analysis - newsline.com
CytomX gains as licensing deal with Regeneron expands - MSN
Schulhoff & Co. Inc. Acquires Shares of 374,850 CytomX Therapeutics, Inc. $CTMX - MarketBeat
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chu Yu-Waye | Chief Medical Officer |
Mar 17 '26 |
Sale |
6.42 |
21,279 |
136,675 |
189,446 |
| McCarthy Sean A. | CEO |
Mar 17 '26 |
Sale |
6.42 |
118,969 |
764,138 |
1,078,922 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 17 '26 |
Sale |
6.42 |
31,492 |
202,273 |
300,760 |
| Ogden Christopher | Chief Financial Officer |
Mar 17 '26 |
Sale |
6.42 |
19,323 |
124,112 |
296,948 |
| McCarthy Sean A. | CEO |
Nov 06 '25 |
Sale |
4.54 |
101,793 |
461,906 |
987,891 |
0.82%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):